[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"feeding-intolerance\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:feeding-intolerance":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,44,76,103],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100642882","fmt-for-feeding-intolerance-due-to-gastrointestinal-dysfunction-in-critically-ill-patients-100642882",false,"NCT07640633","FMT for Feeding Intolerance Due to Gastrointestinal Dysfunction in Critically Ill Patients","Fecal Microbiota Transplantation for Feeding Intolerance Due to Gastrointestinal Dysfunction in Critically Ill Patients: A Single-Center, Single-Blind, Randomized Controlled Trial","FMT-FIT","Inclusion Criteria:\n\n1. Aged 18 to 70 years inclusive, regardless of ethnicity or gender;\n2. Female participants are either non-fertile (i.e., physiologically incapable of pregnancy, including women with ≥2 years of menopause) or have no pregnancy plans;\n3. Have been admitted to the ICU for ≥24 hours;\n4. Expected ICU stay ≥7 days after study enrollment;\n5. Screened positive for ≥1 manifestation of gastrointestinal dysfunction (intra-abdominal hypertension \\[IAH\\], massive gastric retention, diarrhea, lower gastrointestinal paralysis, bowel dilatation); enteral nutrition is then implemented under the guidance of the enteral feeding intolerance (FI) score, and participants with persistent FI after a 3-day trial are formally enrolled;\n6. Participants can actively cooperate or passively complete relevant examinations and follow-up procedures;\n7. Have signed a written informed consent form.\n\nExclusion Criteria:\n\n1. Severe systemic infection in the early resuscitation phase, with hemodynamic instability, insufficient tissue perfusion, or severe fluid-electrolyte and acid-base imbalances;\n2. Patients assessed by clinicians as having a high risk of death within 5 days, or those with restricted treatment decisions;\n3. Active gastrointestinal bleeding, perforation, or other conditions with severe intestinal barrier impairment;\n4. Patients unable to tolerate enteral nutrition meeting 50% of caloric requirements due to severe diarrhea, significant fibrotic intestinal stenosis, massive gastrointestinal bleeding, or high-output enterocutaneous fistula;\n5. Planned or recent abdominal surgery (within 14 days prior to enrollment);\n6. Current diagnosis of fulminant colitis or toxic megacolon;\n7. Neutropenia (neutrophil count \\\u003C 1500 cells\u002FµL);\n8. Patients with congenital or acquired immunodeficiency disorders;\n9. Recent receipt of high-risk immunosuppressive or cytotoxic agents, e.g., rituximab, doxorubicin, or medium-to-high-dose corticosteroids (≥ 20 mg\u002Fday prednisone equivalent) for a duration of \\> 4 weeks;\n10. Pregnant or lactating women;\n11. Participation in another clinical trial as a subject at the time of enrollment or within 3 months prior to enrollment;\n12. Doubtful validity of informed consent: subjects with mental illness, intellectual disability, poor motivation, or other factors that restrict the validity of informed consent for participation in this study.","ALL","18 Years","70 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25],"NA","Critically ill patients admitted to the intensive care unit (ICU) frequently present with gastrointestinal dysfunction and are at elevated risk of malnutrition. Gastrointestinal dysfunction is correlated with adverse clinical outcomes, including prolonged mechanical ventilation duration, extended ICU length of stay, and increased 90-day mortality.\n\nIn critically ill ICU patients, severe gut microbiota dysbiosis and intestinal barrier impairment may occur due to the burden of primary critical illnesses, as well as the administration of proton pump inhibitors and antibiotics. This cascade contributes to a high prevalence of gastrointestinal dysfunction, alongside profound gut-derived systemic inflammatory responses and organ damage. Given the pivotal role of gut microbiota in maintaining intestinal homeostasis, fecal microbiota transplantation (FMT) holds promise as a novel therapeutic strategy for enteral feeding intolerance secondary to gastrointestinal dysfunction in critically ill ICU patients.\n\nThis study intends to deliver FMT via a nasojejunal tube to critically ill patients with gastrointestinal dysfunction admitted to the ICU. Its objectives are to evaluate the intervention's effects on gastrointestinal function recovery and the alleviation of enteral feeding intolerance, while also assessing its impacts on intestinal barrier function, gut microbiota composition and metabolic profiles, serum metabolite signatures, immune-inflammatory responses (including lymphocyte subsets, cytokines, C-reactive protein, and procalcitonin), ICU delirium, ICU sleep quality, and clinical outcomes (encompassing ICU mortality, in-hospital mortality, 28-day all-cause mortality, 90-day all-cause mortality, 90-day readmission rate, and 90-day incidence of secondary infections).",[28,29,30],"Feeding Intolerance","Gastrointestinal Dysfunction","Critically Ill Intensive Care Unit Patients","NOT_YET_RECRUITING","2026-06-05",{"date":34,"type":35},"2026-06-11","ACTUAL",{"date":37,"type":22},"2026-07-01",{"date":39,"type":22},"2027-06-30",{"name":41,"class":42},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":23,"phases":53,"briefSummary":54,"conditions":55,"keywords":60,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":4},"100613772","optimizing-enteral-nutrition-regimen-for-critically-ill-patients-100613772","NCT07270939","Optimizing Enteral Nutrition Regimen for Critically Ill Patients","Optimizing Enteral Nutrition: A Comparative Study of 18-Hour, 20-Hour, and 24-Hour","Inclusion Criteria\n\nParticipants must meet ALL of the following criteria to be eligible for the study:\n\n1. Patients aged ≥ 18 years.\n2. Patients expected to require enteral nutrition (EN) for ≥ 7 days.\n3. Critically ill, mechanically ventilated patients in the ICU.\n4. New patients initiating EN in the critical care unit.\n5. Patients receiving EN via:\n\n   * a nasogastric (NG) tube.\n   * orogastric (OG) feeding tube.\n\nExclusion Criteria:\n\n1. Patients with contraindications to enteral feeding or pre-existing gastrointestinal disorders, including:\n\n   * Active GI bleeding.\n   * Progressive GI disease.\n   * Recent GI tract resection.\n2. Indication for a special diet formula.\n3. Need for a large volume of feeding (as determined by the clinical team).\n4. Pre-existing hepatic failure.\n5. Use of a nasojejunal tube, gastrostomy, or jejunostomy.\n6. Pregnancy confirmed via β-hCG testing for women of childbearing potential.\n7. Insulin-dependent diabetes mellitus.",{"count":52,"type":22},150,[25],"Clinical Trial The goal of this clinical trial is to learn whether different enteral feeding cycles (18-hour, 20-hour, or standard 24-hour continuous feeding) improve outcomes for critically ill ICU patients who need tube feeding. It will also look at tolerance, nutrition delivery, and safety.\n\nThe main questions it aims to answer are:\n\nDo shorter feeding cycles (with fasting windows) reduce ICU length of stay?\n\nDo they lower the risk of infections like ventilator-associated pneumonia?\n\nHow do they affect calorie delivery, blood sugar control, and gastrointestinal tolerance?\n\nResearchers will compare:\n\nContinuous 24-hour feeding (standard care)\n\n20-hour feeding with a 4-hour fasting window\n\n18-hour feeding with a 6-hour fasting window\n\nParticipants will:\n\nBe critically ill adults in the ICU who require at least 7 days of enteral feeding\n\nBe randomized to one of the three feeding schedules\n\nReceive daily monitoring of calories, protein, blood sugar, and GI tolerance\n\nHave outcomes measured, including ICU length of stay, infections, metabolic control, and feeding tolerance",[56,57,58,59,28],"Critical Illness","Enteral Nutrition","Ventilator Associated Pneumonia","Hyperglycemia",[61,62,63,64,65],"Cyclic feeding","Feeding window","Critical care nutrition","Gastrointestinal tolerance","Nutritional adequacy","2025-11-26",{"date":68,"type":35},"2025-12-08",{"date":70,"type":22},"2025-12-30",{"date":72,"type":22},"2026-11-30",{"name":74,"class":75},"Hamad Medical Corporation","INDUSTRY",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":23,"phases":86,"briefSummary":88,"conditions":89,"keywords":90,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":4},"100595363","phase-4-efficacy-of-itopride-versus-metoclopramide-in-hospitalized-medicine-patients-with-high-gastric-residual-volume-100595363","NCT07031479","Efficacy of Itopride Versus Metoclopramide in Hospitalized Medicine Patients With High Gastric Residual Volume","Efficacy of Enteral Itopride Versus Intravenous Metoclopramide in Hospitalized Medicine Patients With Feeding Intolerance Causing by High Gastric Residual Volume: a Prospective Randomized Controlled Trial","GRV","Inclusion Criteria:\n\n* Hospitalized medical patients aged over 18 years who were receiving enteral feeding and had a gastric residual volume (GRV) ≥ 200 ml\n\nExclusion Criteria:\n\n* Use of any prokinetic drug within 24 hours before participating in the study\n* Known hypersensitivity or contraindication to Metoclopramide or Itopride\n* Prolonged QTc interval \\> 460 ms in female \\>440 ms in male\n* Hemodynamic instability\n* GI surgery ≤ 6 weeks before enrollment in the study\n* History of esophagectomy or gastrectomy\n* Pregnancy\n* Suspicious or confirmed gastrointestinal obstruction or gastrointestinal hemorrhage or gastrointestinal perforation\n* Epilepsy or currently use of anti-epileptic drug\n* Acute CNS infection or severe brain injury\n* Parkinson's disease\n* Confirmed or suspected pheochromocytoma\n* History of tardive dyskinesia, history of methemoglobinemia.",{"count":85,"type":22},86,[87],"PHASE4","A prospective randomized controlled trial included 86 patients in medicine ward who were diagnosed with feeding intolerance, defined as having a gastric residual volume greater than 200 ml. The patients were randomly assigned to two treatment groups: one receiving enteral metoclopramide and the other receiving intravenous metoclopramide. The primary outcome was the gastric residual volume at 72 hours after treatment. The secondary outcome was gastric residual volume at 24 hours and 7 days after treatment, administered-to-prescribed volume at 72 hours after treatment, the administered-to-target energy ratio and the administered-to-target protein ratio at 96 hours after treatment, the nutrition status evaluated by the Nutrition Alert Form at 7 days after treatment, incidence of adverse events (arrhythmia, pneumonia, diarrhea, vomiting, aspiration), length of hospital stay, ICU length of stay and in-hospital mortality.",[28],[91,92,93],"gastric residual volume","metoclopramide","itopride","2025-06-19",{"date":96,"type":35},"2025-06-22",{"date":98,"type":22},"2025-07-01",{"date":100,"type":22},"2026-09-30",{"name":102,"class":42},"Chulalongkorn University",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":17,"minAge":110,"maxAge":111,"enrollmentInfo":112,"targetDuration":4,"studyType":23,"phases":114,"briefSummary":115,"conditions":116,"keywords":118,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":43},"100579244","gastric-feeding-versus-transpyloric-feeding-in-infants-with-severe-bronchopulmonary-dysplasia-a-crossover-study-100579244","NCT06821776","Gastric Feeding Versus Transpyloric Feeding in Infants with Severe Bronchopulmonary Dysplasia, a Crossover Study","N-of-1 Trial Comparing Prolonged Gastric Feeding to Transpyloric Feeding in Infants with Severe Bronchopulmonary Dysplasia","Inclusion Criteria:\n\n* Patients born \\\u003C32 weeks' gestation\n* Currently admitted to the Le Bonheur NICU\n* Grad 2 or 3 BPD (positive pressure or intubated at 36 weeks PMA)\n* Signs of gastroesophageal reflux, chronic aspiration, or other feeding intolerance.\n\nExclusion Criteria:\n\n* Known gastrointestinal anomalies\n* Unable to tolerate ≥100mL\u002Fkg\u002Fday enteral feeding\n* Congenital anomalies likely to alter feeding techniques\n* Surgical feeding tube in place or expected within the next 8 weeks\n* Expected to remain hospitalized \\\u003C8 weeks","1 Month","1 Year",{"count":113,"type":22},25,[25],"Hospitalized infants with severe bronchopulmonary dysplasia (BPD) and feeding intolerance will be randomized to 2 weeks of continuous gastric feeding or continuous transpyoloric feeding. Subjects will crossover after 2 weeks and receive 4 weeks of each feeding mode. Respiratory status will be assessed to determine the optimal feeding mode for each infant.",[117,28],"Bronchopulmonary Dysplasia",[119],"BPD","RECRUITING","2025-02-06",{"date":123,"type":35},"2025-02-12",{"date":125,"type":35},"2025-02-05",{"date":127,"type":22},"2030-02",{"name":129,"class":42},"Le Bonheur Children's Hospital"]